TB-500 is a commonly searched research peptide, often paired with BPC-157, and the questions to settle before ordering are the familiar ones: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary. It is not a guide to any use, not a claim that TB-500 is an authorized drug or suitable for human use, and not legal or medical advice.

Identity starts with the named compound

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ — the N-acetylated active fragment corresponding to amino acids 17–23 of the endogenous signalling factor thymosin beta-4 (Tβ4). It is worth being precise here: TB-500 is not identical to full-length thymosin beta-4, but a short fragment of it, which is why a listing is more accurate when it describes the material as a thymosin beta-4 fragment rather than as Tβ4 itself. A procurement record should begin with the compound name, that identity, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document. Those fields establish identity for reconciliation; they do not verify biological activity or authorize a route of use.

Research status

TB-500 has been documented largely in preclinical and veterinary contexts — it has been encountered as a designer substance in racehorses — and human clinical evidence is limited. The existence of research interest in a named compound documents investigation; it does not establish that a third-party research material is an authorized drug product, equivalent to any study material, or suitable for human use. This article makes no claim about effects.

Canadian and anti-doping regulatory context

Health Canada’s April 2026 public advisory on unauthorized injectable peptides names TB-500 among the products it identifies, and states that unauthorized drug products are illegal in Canada and have not been assessed for safety, efficacy, and quality by Health Canada. TB-500 is not approved for human clinical use, has been classified as a prescription medicine in some jurisdictions such as Australia and New Zealand, and is prohibited by the World Anti-Doping Agency for athletes in competition — relevant to any research setting connected to sport.

The advisory is also explicit that a “research use only” label “does not make these products legal or exempt from regulatory requirements.” Vitatide’s research-use wording should be read the same way — a use boundary, not a claim of regulatory authorization — and determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.

Read the Health Canada public advisory

What a CoA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. For TB-500 as for any compound, the checks are the same:

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.